Company profile
Mironid Limited
Bot Verification
Mironid Limited is a UK company with status active founded in 2014.
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Capital Allotment Shares
CapitalSH01 | Transaction MzUyNDMzNzc5NWFkaXF6a2N4
Published 29 May 2026 15:02
Resolution
ResolutionRESOLUTIONS | Transaction WUVaUDBZOVNhZGlxemtjeA | Paper/PDF filed
Published 10 Apr 2026 13:24
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Small
Accounts PDF pendingAA | Transaction MzQzNzY4NzkzMmFkaXF6a2N4 | Paper/PDF filed
Published 02 Oct 2024 06:15
Confirmation Statement With No Updates
Confirmation-statementCS01 | Transaction MzQzNzY3NjQ3MGFkaXF6a2N4
Published 30 Sep 2024 08:04
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Extending Mironid's PDE4 activator programme: Hyperparathyroidism as a second clinical indication
1 Mar 2023 to 29 Feb 2024
Human parathyroid hormone (PTH) is produced by four parathyroid glands located in the neck and regulates the level of calcium and phosphate in the blood by controlling reabsorption from urine, uptake from the digestive tract and resorption from calcium reservoirs in the bone. Hyperparathyroidism results in excessive release of parathyroid hormone into the...
Small molecule activators of cAMP PDE4 long isoforms for immuno-oncology
1 Apr 2018 to 30 Jun 2019
According to the World Health Organisation 8.8 million people died of cancer in 2015: 1 in 6 of all global deaths. Tumours are able to hide from the immune system, avoiding detection and removal by the body's natural defences. The ability to reveal tumours to the immune system by overcoming cloaking processes, the core of immuno-oncology, is showing great...
Small molecule activators of cAMP PDE4 long isoforms for the treatment of ADPKD
1 Jan 2017 to 30 Sep 2017
Autosomal dominant polycystic kidney disease (ADPKD) is a life-threatening and currently incurable genetic disorder of the kidneys characterised by the development of pathological cysts. It affects some 12.5 million people worldwide, with around 50% of sufferers requiring treatment for kidney failure by the age of 60. Mironid is applying its unique unders...